Impact Biomedical (NYSEAMERICAN:IBO – Get Free Report) released its quarterly earnings results on Monday. The company reported ($0.08) earnings per share for the quarter, FiscalAI reports. The company had revenue of $0.02 million during the quarter. Impact Biomedical had a net margin of 4,247.37% and a return on equity of 10.87%.
Impact Biomedical Stock Down 1.5%
Shares of IBO opened at $4.55 on Wednesday. Impact Biomedical has a 1-year low of $2.43 and a 1-year high of $10.47. The firm’s 50-day moving average price is $4.95 and its 200-day moving average price is $6.18.
About Impact Biomedical
Impact BioMedical, Inc. is a biotechnology company focused on developing biomedical technologies and products intended to address public-health and healthcare needs. Its activities have included research into antiviral, antimicrobial, immunomodulatory and other therapeutic applications. The company has been associated with the development of Equivir, an antiviral technology described as having potential broad-spectrum applications. Impact BioMedical has also pursued intellectual property and product-development opportunities in areas such as infectious disease prevention, immune support and related biomedical solutions.
Recommended Stories
- Five stocks we like better than Impact Biomedical
- 3 Stocks Wall Street Likes More Than the Market Does
- Anthropic’s Trillion-Dollar IPO Could Give Cloud Giants a Double Win
- The AI Debt Bill Is Coming Due, But Biotech Has Revenue to Show for the Boom
- 3 Insider Selling Stories; 3 Different Signals for Investors
Receive News & Ratings for Impact Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impact Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.
